World Leaders Tackle Vaccine Hesitancy At Global Summit 12/09/2019 Grace Ren At a first-ever Global Vaccination Summit, health leaders worldwide ramped up efforts to tackle “vaccine hesitancy”, which has prompted the recent resurgence of vaccine-preventable diseases such as measles. “After many years of progress, we are at a critical turning point. Measles is resurging, and 1 in 10 children continues to miss out on essential childhood […] Continue reading -> AI & Healthcare Conference Considers Access, Equity & Gender 11/09/2019 Elaine Ruth Fletcher Digital health holds the potential to transform health systems so that they become more proactive and responsive to patients, advocates said at Wednesday’s launch of a two-day international conference that brought together members of the global healthcare and artificial intelligence (AI) communities in Switzerland’s pharmaceutical industry hub, Basel. But using AI doesn’t inherently empower women […] Continue reading -> Malaria Eradication Feasible by 2050, Says New Lancet Report 09/09/2019 Grace Ren A new Lancet Commission report calls for health policy leaders to agree upon an ambitious global plan to eradicate of malaria by 2050 – contrasting with a World Health Organization report released in August that concluded it was too early to set a target date for eradication. The report Malaria eradication within a generation: ambitious, […] Continue reading -> WHO To Revisit Guidelines On Ebola Survivors’ Care; Study Finds 5-fold Higher Mortality 06/09/2019 Grace Ren New data revealing that survivors of Guinea’s 2013-16 Ebola outbreak were five times more likely to die within the first year after recovery, as compared to the general population, suggests a need to revisit WHO guidance on Ebola survivors’ monitoring and care, a top WHO official said on Friday. The findings were part of a […] Continue reading -> Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
AI & Healthcare Conference Considers Access, Equity & Gender 11/09/2019 Elaine Ruth Fletcher Digital health holds the potential to transform health systems so that they become more proactive and responsive to patients, advocates said at Wednesday’s launch of a two-day international conference that brought together members of the global healthcare and artificial intelligence (AI) communities in Switzerland’s pharmaceutical industry hub, Basel. But using AI doesn’t inherently empower women […] Continue reading -> Malaria Eradication Feasible by 2050, Says New Lancet Report 09/09/2019 Grace Ren A new Lancet Commission report calls for health policy leaders to agree upon an ambitious global plan to eradicate of malaria by 2050 – contrasting with a World Health Organization report released in August that concluded it was too early to set a target date for eradication. The report Malaria eradication within a generation: ambitious, […] Continue reading -> WHO To Revisit Guidelines On Ebola Survivors’ Care; Study Finds 5-fold Higher Mortality 06/09/2019 Grace Ren New data revealing that survivors of Guinea’s 2013-16 Ebola outbreak were five times more likely to die within the first year after recovery, as compared to the general population, suggests a need to revisit WHO guidance on Ebola survivors’ monitoring and care, a top WHO official said on Friday. The findings were part of a […] Continue reading -> Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Malaria Eradication Feasible by 2050, Says New Lancet Report 09/09/2019 Grace Ren A new Lancet Commission report calls for health policy leaders to agree upon an ambitious global plan to eradicate of malaria by 2050 – contrasting with a World Health Organization report released in August that concluded it was too early to set a target date for eradication. The report Malaria eradication within a generation: ambitious, […] Continue reading -> WHO To Revisit Guidelines On Ebola Survivors’ Care; Study Finds 5-fold Higher Mortality 06/09/2019 Grace Ren New data revealing that survivors of Guinea’s 2013-16 Ebola outbreak were five times more likely to die within the first year after recovery, as compared to the general population, suggests a need to revisit WHO guidance on Ebola survivors’ monitoring and care, a top WHO official said on Friday. The findings were part of a […] Continue reading -> Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO To Revisit Guidelines On Ebola Survivors’ Care; Study Finds 5-fold Higher Mortality 06/09/2019 Grace Ren New data revealing that survivors of Guinea’s 2013-16 Ebola outbreak were five times more likely to die within the first year after recovery, as compared to the general population, suggests a need to revisit WHO guidance on Ebola survivors’ monitoring and care, a top WHO official said on Friday. The findings were part of a […] Continue reading -> Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Facebook Moves To Squash Vaccine Misinformation; WHO Website Now A Top Pick 05/09/2019 Elaine Ruth Fletcher Facebook has begun rolling out a new algorithm that directs users searching for vaccine information to the United States Centers for Disease Control (CDC) website, in the case of US-based searches, and for users elsewhere, the World Health Organization website, as a top search pick. The move was welcomed by WHO, officials at CDC, and […] Continue reading -> FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
FDA Approves New Treatment For Drug-Resistant TB; Activists Call For Affordable Access 19/08/2019 Grace Ren The US Food and Drug Administration (FDA) last week approved a tuberculosis (TB) treatment regimen containing a new drug, pretomanid, offering a shorter, more effective course of treatment for highly drug-resistant strains of TB, the world’s leading cause of death by infectious disease. Pretomanid is only the third TB drug to be approved in over […] Continue reading -> FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis 15/08/2019 Press release [TB Alliance] NEW YORK (August 14, 2019)—Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis (TB).1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) […] Continue reading -> How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
How To Fix The Medical R&D Model 14/08/2019 David Branigan Fifa Rahman, Unitaid NGO Delegation board member and PhD Candidate at the University of Leeds, moderated a panel at the recent IAS Conference on HIV Science in Mexico entitled “How To Fix Our Medical R&D Model: A Spotlight On TB Treatment.” The panel featured speakers from Médecins Sans Frontières’ (MSF/Doctors Without Borders) Access Campaign, Drugs […] Continue reading -> Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates 12/08/2019 Press release [US National Institutes of Health] 12 August, 2019 The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) […] Continue reading -> GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute 09/08/2019 Press release [Sabin Vaccine Institute] LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently available. […] Continue reading -> Posts navigation Older postsNewer posts